<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JCO Oncol Pract</journal-id><journal-id journal-id-type="iso-abbrev">JCO Oncol Pract</journal-id><journal-id journal-id-type="pmc-domain-id">3790</journal-id><journal-id journal-id-type="pmc-domain">jcoop</journal-id><journal-id journal-id-type="publisher-id">OP</journal-id><journal-title-group><journal-title>JCO Oncology Practice</journal-title></journal-title-group><issn pub-type="ppub">2688-1527</issn><issn pub-type="epub">2688-1535</issn><publisher><publisher-name>American Society of Clinical Oncology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9213200</article-id><article-id pub-id-type="pmcid-ver">PMC9213200.1</article-id><article-id pub-id-type="pmcaid">9213200</article-id><article-id pub-id-type="pmcaiid">9213200</article-id><article-id pub-id-type="pmid">34558297</article-id><article-id pub-id-type="doi">10.1200/OP.21.00466</article-id><article-id pub-id-type="publisher-id">OP.21.00466</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>ORIGINAL CONTRIBUTIONS</subject><subj-group><subject>Care Delivery</subject></subj-group></subj-group></article-categories><title-group><article-title>Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0875-4731</contrib-id><name name-style="western"><surname>Gupta</surname><given-names initials="A">Arjun</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nshuti</surname><given-names initials="L">Leonce</given-names></name><degrees>MS</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9638-3629</contrib-id><name name-style="western"><surname>Grewal</surname><given-names initials="US">Udhayvir S.</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8937-0726</contrib-id><name name-style="western"><surname>Sedhom</surname><given-names initials="R">Ramy</given-names></name><degrees>MD</degrees><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0673-879X</contrib-id><name name-style="western"><surname>Check</surname><given-names initials="DK">Devon K.</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Parsons</surname><given-names initials="HM">Helen M.</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5433-4810</contrib-id><name name-style="western"><surname>Blaes</surname><given-names initials="AH">Anne H.</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Virnig</surname><given-names initials="BA">Beth A.</given-names></name><degrees>PhD, MPH</degrees><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lustberg</surname><given-names initials="MB">Maryam B.</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0758-7911</contrib-id><name name-style="western"><surname>Subbiah</surname><given-names initials="IM">Ishwaria M.</given-names></name><degrees>MD</degrees><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4577-3248</contrib-id><name name-style="western"><surname>Nipp</surname><given-names initials="RD">Ryan D.</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6530-7415</contrib-id><name name-style="western"><surname>Dy</surname><given-names initials="SM">Sydney M.</given-names></name><degrees>MD</degrees><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3907-9196</contrib-id><name name-style="western"><surname>Dusetzina</surname><given-names initials="SB">Stacie B.</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label><sup>1</sup></label>Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN</aff><aff id="aff2"><label><sup>2</sup></label>Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN</aff><aff id="aff3"><label><sup>3</sup></label>Department of Internal Medicine, Louisiana State University, Shreveport, LA</aff><aff id="aff4"><label><sup>4</sup></label>Division of Oncology, University of Pennsylvania, PA</aff><aff id="aff5"><label><sup>5</sup></label>Department of Population Health Sciences, Duke University School of Medicine, Durham, NC</aff><aff id="aff6"><label><sup>6</sup></label>Division of Health Policy and Management, University of Minnesota, Minneapolis, MN</aff><aff id="aff7"><label><sup>7</sup></label>Department of Hematology Oncology, Yale Cancer Center, New Haven, CT</aff><aff id="aff8"><label><sup>8</sup></label>Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX</aff><aff id="aff9"><label><sup>9</sup></label>Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA</aff><aff id="aff10"><label><sup>10</sup></label>Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD</aff></contrib-group><author-notes><corresp id="cor1">Stacie B. Dusetzina, PhD, Department of Health Policy, Vanderbilt University School of Medicine, 2525 West End Ave, Ste 1203, Nashville, TN 37203; e-mail: <email>s.dusetzina@vanderbilt.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>9</month><year>2021</year></pub-date><volume>18</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">410607</issue-id><fpage>140</fpage><lpage>147</lpage><history><date date-type="received"><day>21</day><month>6</month><year>2021</year></date><date date-type="rev-recd"><day>28</day><month>7</month><year>2021</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>09</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>22</day><month>06</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-21 16:25:26.393"><day>21</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by American Society of Clinical Oncology</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>American Society of Clinical Oncology</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="op-18-0140.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="op-18-0140.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="companion" xml:lang="en" xlink:title="editorial" journal-id="JCO Oncol Pract" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC9213193"><article-title>What Oncologists Must Account for: The Financial Burden of Cancer-Associated Symptom Relief</article-title><volume>18</volume><issue>2</issue><date><day>30</day><month>11</month><year>2021</year></date><fpage>106</fpage><lpage>108</lpage><source>JCO Oncology Practice</source><pub-id pub-id-type="pmcid">PMC9213193</pub-id><pub-id pub-id-type="pmid">34846913</pub-id></related-article><abstract><title>PURPOSE:</title><p>The financial toxicity of anticancer drugs is well-documented, but little is known about the costs of drugs used to manage cancer-associated symptoms.</p><sec><title>METHODS:</title><p>We reviewed relevant guidelines and compiled drugs used to manage seven cancer-associated symptoms (anorexia and cachexia, chemotherapy-induced peripheral neuropathy, constipation, diarrhea, exocrine pancreatic insufficiency, cancer-associated fatigue, and chemotherapy-induced nausea and vomiting). Using GoodRx website, we identified the retail price (cash price at retail pharmacies) and lowest price (discounted, best-case scenario of out-of-pocket costs) for patients without insurance for each drug or formulation for a typical fill. We describe lowest prices here.</p></sec><sec><title>RESULTS:</title><p>For anorexia and cachexia, costs ranged from $5 US dollars (USD; generic olanzapine or mirtazapine tablets) to $1,156 USD (brand-name dronabinol solution) and varied widely by formulation of the same drug or dosage: for olanzapine 5 mg, $5 USD (generic tablet) to $239 USD (brand-name orally disintegrating tablet). For chemotherapy-induced peripheral neuropathy, costs of duloxetine varied from $12 USD (generic) to $529 USD (brand-name). For constipation, the cost of sennosides or polyethylene glycol was &lt;$15 USD, whereas newer agents such as methylnaltrexone were expensive ($1,001 USD). For diarrhea, the cost of generic loperamide or diphenoxylate-atropine tablets was &lt;$15 USD. For exocrine pancreatic insufficiency, only brand-name formulations were available, range of cost, $1,072 USD-$1,514 USD. For cancer-associated fatigue, the cost of generic dexamethasone or dexmethylphenidate was &lt;$15 USD, whereas brand-name modafinil was more costly ($1,284 USD). For a 4-drug nausea and vomiting prophylaxis regimen, costs ranged from $181 USD to $1,430 USD.</p></sec><sec><title>CONCLUSION:</title><p>We highlight the high costs of many symptom control drugs and the wide variation in the costs of these drugs. These findings can guide patient-clinician discussions about cost-effectively managing symptoms, while promoting the use of less expensive formulations when possible.</p></sec></abstract><counts><fig-count count="8"/><table-count count="0"/><equation-count count="0"/><ref-count count="56"/><page-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>INTRODUCTION</title><p>The high and ever rising costs of cancer drugs are well-recognized: for Medicare Part D beneficiaries, the average monthly point-of-sale price for oral anticancer drugs was nearly $14,000 US dollars (USD) in 2018, with estimated annual out-of-pocket costs for patients exceeding $10,000 USD.<sup><xref rid="b1" ref-type="bibr">1</xref></sup> In contrast to these costs, the financial burden of symptom control drugs in oncology has received less attention.<sup><xref rid="b2" ref-type="bibr">2</xref></sup> Traditionally, patients and clinicians often use lower-cost generics, frequently available over-the-counter, to control symptoms. Because the costs of these individual products are low relative to that of anticancer drugs, their cost-related burdens have largely escaped attention.</p><p>In recent years, newer symptom control drugs have come into more widespread use, leading to increased health care spending,<sup><xref rid="b3" ref-type="bibr">3</xref></sup> despite narrow indications and sometimes limited benefits of these drugs over existing, predominately generic drugs.<sup><xref rid="b4" ref-type="bibr">4</xref></sup> One example is peripheral &#956;-opioid receptor antagonists (PAMORAs) for opioid-induced constipation. Medicare Part D spending on PAMORAs increased from $13.6 million USD to more than $150 million USD between 2014 and 2018.<sup><xref rid="b3" ref-type="bibr">3</xref></sup> Adding to patient-level financial toxicity, clinicians often prescribe symptom control drugs urgently in response to a symptom crisis, at a time when arranging financial support is either not considered or not feasible. For example, when a patient with cancer is actively vomiting, they need an urgent supply of antiemetics without the opportunity to consider whether a savings card, a generic formulation of the same drug, or an alternative (but reasonable) drug could provide substantial savings. Previous research suggests that even small copays can lead to prescription abandonment, with one study demonstrating that among more than 38,000 insured patients with cancer, a copay of &lt;$10 USD was associated with a 10% rate of abandonment.<sup><xref rid="b5" ref-type="bibr">5</xref></sup> Additionally, patients can experience significant financial burdens from being nickel-and-dimed from seemingly small but repetitive costs, such as those associated with transportation and parking.<sup><xref rid="b6" ref-type="bibr">6</xref></sup></p><p>Perhaps more concerning, there is often limited evidence supporting the clinical benefits of many symptom control drugs, yet they are widely used. For example, data are lacking to support the routine use of gabapentinoids for chemotherapy-induced peripheral neuropathy, but clinicians often prescribe these agents.<sup><xref rid="b7" ref-type="bibr">7</xref>,<xref rid="b8" ref-type="bibr">8</xref></sup> In addition to a lack of efficacy, these agents can contribute to patients' side effect profile through direct adverse events and drug-drug interactions and they may further result in financial toxicity. For most cancer-associated symptoms, several drug options often exist, with costs varying widely across treatment options. For example, the point-of-sale price for a single 8 mg dose of oral ondansetron can vary 14-fold ($6.50 USD for a generic tablet to $85 USD for a brand-name oral disintegrating tablet).<sup><xref rid="b9" ref-type="bibr">9</xref></sup> The differences in costs across different drugs can be even more substantial.</p><p>For many patients, their prescription drug coverage is sufficiently limited that it may in effect be totally lacking, and in 2019, among adults age under 65 years, 14.7% were uninsured.<sup><xref rid="b10" ref-type="bibr">10</xref></sup> In 2018, 45% of adults age under 65 years were inadequately insured (22.6% underinsured, 10.0% coverage gap, and 12.4% uninsured).<sup><xref rid="b11" ref-type="bibr">11</xref></sup> Thus, we aimed to assess the average retail costs and the lowest available costs for cash-paying patients for drugs used to manage common cancer-associated symptoms. This information can help clinicians to understand the range of costs for prescribed or over-the-counter options for their patients and to inform cost-conscious prescribing when clinical benefits are similar among treatment alternatives.</p></sec><sec sec-type="methods"><title>METHODS</title><p>We conducted a cross-sectional, descriptive study reviewing oncology, supportive care, and gastroenterology societies' guidelines to identify patient-administered (largely oral) drugs used to manage seven common cancer-associated symptoms or conditions. Specifically, we focused on the following: (1) anorexia and cachexia, (2) cancer-associated fatigue, (3) chemotherapy-induced nausea and vomiting prophylaxis and treatment, (4) chemotherapy-induced peripheral neuropathy, (5) constipation, (6) diarrhea, and (7) exocrine pancreatic insufficiency.<sup><xref rid="b8" ref-type="bibr">8</xref>,<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b12" ref-type="bibr">12</xref>-<xref rid="b24" ref-type="bibr">24</xref></sup> We selected these symptoms on the basis of their pervasiveness, impact on patients' quality of life, and the availability of several drugs to manage these symptoms.<sup><xref rid="b25" ref-type="bibr">25</xref>,<xref rid="b26" ref-type="bibr">26</xref></sup> We did not include some symptoms, either because of complex management (eg, pain) or because few symptom-specific drugs are available for treatment (eg, breathlessness, mucositis, and aromatase inhibitor&#8211;associated musculoskeletal symptoms).<sup><xref rid="b27" ref-type="bibr">27</xref>-<xref rid="b32" ref-type="bibr">32</xref></sup> We also included drugs commonly encountered in clinical practice, even if data to support their routine use are limited and/or guidelines do not recommend their use; we used UpToDate, Inc and authors' experience to guide the final selection of included drugs. We only included drugs focused on symptom palliation and not drugs reversing an underlying disease process (eg, we did not include corticosteroids or infliximab for managing diarrhea related to immune-medicated colitis), regardless of whether they had a US Food and Drug Administration&#8211;approved symptom control indication, as in clinical practice, clinicians often use symptom control drugs off-label. As an example, there are currently no drugs approved to treat cancer-associated anorexia and cachexia, but pharmacologic intervention is common.<sup><xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b33" ref-type="bibr">33</xref>,<xref rid="b34" ref-type="bibr">34</xref></sup> We excluded drugs not available in the United States.</p><p>We compiled all formulations of a drug (eg, tablet, capsule, and solution) commonly used in clinical practice and separately considered brand name and generic versions of each product. We excluded parenteral drugs (eg, intravenous fosnetupitant and fosaprepitant for chemotherapy-induced nausea and vomiting, subcutaneous octreotide for diarrhea, etc).<sup><xref rid="b13" ref-type="bibr">13</xref></sup> Excluded drugs are listed in the Data Supplement (online only). Using the most commonly used dosage (strength) of that drug and the typical time course of prescription for a particular symptom using clinical guidelines and clinical judgment, we calculated a typical quantity (fill) of that drug. As examples, (1) for anorexia and cachexia, a 2-week trial of drugs is recommended<sup><xref rid="b16" ref-type="bibr">16</xref></sup> and (2) the average requirement of pancreatic enzymes in people with exocrine pancreatic insufficiency is 250,000 USP units of lipase per day and a 2-week trial is often prescribed.<sup><xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b35" ref-type="bibr">35</xref></sup></p><p>We used GoodRx website,<sup><xref rid="b36" ref-type="bibr">36</xref></sup> a nationally available drug price comparison website that provides real-time information on drug prices available to consumers at participating pharmacies in their zip code.<sup><xref rid="b37" ref-type="bibr">37</xref>,<xref rid="b38" ref-type="bibr">38</xref></sup> From GoodRx website,<sup><xref rid="b36" ref-type="bibr">36</xref></sup> we extracted the average retail price and the lowest price with coupons for each drug or formulation. The retail price (also called the cash price) is the price at a retail pharmacy for patients who either do not have prescription drug coverage or elect not to fill a prescription through insurance (most commonly because of noncoverage of the drug under the health plan or because the costs with coupons would be lower than the costs with insurance). The retail price reflects the prerebate price per fill and approximates the drug's list price. The lowest price reflects discounts offered under contracts between GoodRx<sup><xref rid="b36" ref-type="bibr">36</xref></sup> and pharmacy benefits managers and are available to patients using pharmacy and drug-specific coupons available on the GoodRx website.<sup><xref rid="b36" ref-type="bibr">36</xref></sup> The lowest price represents a best-case scenario of out-of-pocket costs for a patient without insurance or those electing not to use prescription drug coverage.</p><p>We collected data for a single zip code (10065, Upper East Side, Manhattan) for a single month (May 2021) to minimize geographic and temporal variation. We selected this zip code to be consistent with pricing information available in ASCO guidelines and prior methodology on cancer drug pricing.<sup><xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b13" ref-type="bibr">13</xref>,<xref rid="b16" ref-type="bibr">16</xref>,<xref rid="b39" ref-type="bibr">39</xref></sup></p><p>Institutional review board approval was not required because the study did not involve human subjects research. We used Microsoft Excel v16.0 (Redmond, WA) and GraphPad Prism v7.0 (San Diego, CA) for analyses.</p></sec><sec sec-type="results"><title>RESULTS</title><p>We present the results for each symptom individually in graphical form (Figs <xref rid="fig1" ref-type="fig">1</xref>-<xref rid="fig3" ref-type="fig">3</xref> and Appendix Figs A<xref rid="figA1" ref-type="fig">1</xref>-A<xref rid="figA5" ref-type="fig">5</xref>, online only). For each symptom, we present details about the drugs (formulations, dosages, use patterns, and typical fill or quantity) in the Data Supplement. We highlight key results in the following text:</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>FIG 1.</label><caption><p>Range of costs of drugs used to manage anorexia and cachexia for a typical fill (2 weeks). USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g002.jpg"/></fig><sec><title>Anorexia and Cachexia</title><p>We included seven drugs available in 20 formulations prescribed to treat cancer-associated anorexia and cachexia (Fig <xref rid="fig1" ref-type="fig">1</xref>). For a 2-week fill, average retail prices were lowest for generic metoclopramide and mirtazapine tablets ($16 USD and $20 USD, respectively) and highest for brand-name solutions of megestrol acetate (Megace ES) and dronabinol (Syndros; $729 USD and $1,440 USD, respectively). For cash-paying patients with coupons, the lowest price for these drugs was $5 USD/fill for generic olanzapine and mirtazapine tablets and $606 USD and $1,156 USD for brand-name megestrol acetate and dronabinol solutions, respectively. Costs also varied widely by formulations of the same drug or dosage: for 15 units of olanzapine 5 mg, from $5 USD (generic olanzapine tablet) to $239 USD (brand-name orally disintegrating tablet).</p></sec><sec><title>Cancer-Associated Fatigue</title><p>We included four drugs available in eight formulations for managing cancer-associated fatigue (Fig <xref rid="fig2" ref-type="fig">2</xref>). For a 2-week supply, the average retail price was lowest for generic dexamethasone tablets ($26 USD) and highest for brand-name modafinil tablets ($1,492 USD). Mirroring the retail prices, for cash-paying patients with coupons, the lowest prices for these drugs were $12 USD for dexamethasone tablets and $1,284 USD for brand-name modafinil tablets. For generic modafinil tablets, the average retail price was $565 USD and the lowest price was $17 USD.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>FIG 2.</label><caption><p>Range of costs of drugs used to manage cancer-associated fatigue for a typical fill (2 weeks). USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g003.jpg"/></fig></sec><sec><title>Chemotherapy-Induced Nausea and Vomiting Prophylaxis and Treatment</title><p>For chemotherapy-induced nausea and vomiting prophylaxis, we included 10 drugs in 21 formulations (Fig <xref rid="fig3" ref-type="fig">3</xref>). For Neurokinin-1-(NK1)-receptor antagonists, administered with highly emetogenic chemotherapy, options included generic aprepitant, brand-name aprepitant, brand-name rolapitant, and brand-name combined NK1-receptor and serotonin (5HT3)-receptor antagonists (netupitant and palonosetron capsule). For a single chemotherapy cycle, the average retail price of these products ranged from $684 USD to $795 USD. The lowest cost of generic aprepitant was $174 USD, whereas the lowest price of brand-name products was $643 USD-$770 USD.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>FIG 3.</label><caption><p>Range of costs of drugs used to prevent chemotherapy-induced nausea and vomiting for a typical fill (1 dose/cycle of chemotherapy). 5-HT3, serotonin; HEC, highly emetogenic chemotherapy; NK1, Neurokinin-1; USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g004.jpg"/></fig><p>Among 5HT3-receptor antagonists, for a single chemotherapy cycle, the average retail price ranged from $11 USD (generic ondansetron tablet) to $683 USD (brand-name granisetron transdermal patch). Mirroring this, the cash price with coupons was lowest for generic ondansetron tablet ($1 USD) and highest for brand-name granisetron transdermal patch ($605 USD).</p><p>Different combinations of these drugs are used for prophylaxis depending on the emetogenic potential of the chemotherapy agent(s). The Data Supplement demonstrates that for a 4-drug antiemetic regimen for a highly emetogenic chemotherapy (eg, cisplatin), consisting of an NK1-receptor antagonist (days 1-3 if aprepitant used), a 5HT3-receptor antagonist (day 1), dexamethasone (days 1-4), and olanzapine (days 1-4), the cash price with coupons can vary from $181 USD to $1,430 USD.</p><p>For treating breakthrough chemotherapy-induced nausea and vomiting, we included 12 drugs in 23 formulations (Appendix Fig A<xref rid="figA5" ref-type="fig">5</xref>). For a 1-week fill, the average retail price was lowest for generic metoclopramide ($8 USD) and promethazine ($11 USD) tablets and high for brand-name dronabinol solution ($1,440 USD), dolasetron tablets ($1,060 USD), and brand-name ondansetron oral dissolving film ($662 USD). The cash price with coupons was lowest for generic tablets of olanzapine ($2 USD), metoclopramide, ondansetron, promethazine, and lorazepam ($3 USD each) and generic ondansetron oral disintegrating tablets ($5 USD).</p><p>The cash price with coupons also varied widely by formulations of the same drug or dosage: for 15 units of ondansetron 4 mg, it varied from $3 USD (generic tablet), $5 USD (generic, oral disintegrating tablets), $349 USD (brand-name tablet), to $516 USD (brand-name oral dissolving film).</p></sec><sec><title>Chemotherapy-Induced Peripheral Neuropathy</title><p>We included six drugs available in 13 formulations used to treat chemotherapy-induced peripheral neuropathy (Appendix Fig A<xref rid="figA1" ref-type="fig">1</xref>). For a 30-day fill, the average retail price of duloxetine formulations was $241 USD (generic capsule) and $637 USD (brand-name capsule, Cymbalta). For cash-paying patients with coupons, the lowest price for duloxetine formulations was $12 USD (generic capsule) and $529 USD (brand-name capsule, Cymbalta). Generic formulations of all drugs were less expensive (lowest price, &lt; $15 USD), whereas brand-name formulations were very costly (eg, for brand-name nortriptyline capsules, average retail price $1,426 USD and lowest price $1,168 USD).</p></sec><sec><title>Constipation</title><p>We included 11 drugs available in 19 formulations used to treat constipation (Appendix Fig A<xref rid="figA2" ref-type="fig">2</xref>). For a 2-week fill, average retail prices were lowest for over-the-counter, traditional laxatives such as bisacodyl ($4 USD), docusate ($4 USD), sennosides ($6 USD), and magnesium-containing solutions ($6 USD). These drugs also had low lowest prices ($1 USD-$3 USD). Novel drugs used to treat laxative-refractory opioid-induced constipation (such as PAMORAs and lubiprostone) were more costly: the average retail price and lowest price for methylnaltrexone, a PAMORA, were $1,170 USD and $1,001 USD, respectively.</p></sec><sec><title>Diarrhea</title><p>We included three drugs available in six formulations used to treat diarrhea (Appendix Fig A<xref rid="figA3" ref-type="fig">3</xref>). For a 1-week fill, average retail prices were lowest for generic loperamide capsule ($26 USD) and generic diphenoxylate and atropine tablets ($28 USD) and highest for diphenoxylate and atropine formulations (brand-name tablets, $122 USD, and solution, $114 USD). For cash-paying patients with coupons, the lowest price for these drugs was $6 USD for generic cholestyramine packets and $95 USD for brand-name diphenoxylate and atropine tablets.</p></sec><sec><title>Exocrine Pancreatic Insufficiency</title><p>We included five formulations of PERT for managing exocrine pancreatic insufficiency (Appendix Fig A<xref rid="figA4" ref-type="fig">4</xref>). All formulations were brand-name products, and there were no generic formulations. For a 15-day supply, average retail prices ranged from $1,288 USD to $1,860 USD. For cash-paying patients with coupons, the lowest price for these drugs ranged from $1,072 USD-$1,514 USD.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>In this cross-sectional, descriptive study, we noted a wide range in costs of drugs used to manage common symptoms experienced by patients with cancer, which could add to the financial burden of patients. As expected, the use of brand-name preparations and more complex formulations (solutions or oral disintegrating tablets) was very costly for patients. Although many patients have insurance that helps to lower the out-of-pocket costs, when both generic and brand alternatives are available, the brand-name alternatives may not be covered by a patient's insurance, requiring patients to pay full retail prices for these products if the brand name is prescribed.<sup><xref rid="b40" ref-type="bibr">40</xref></sup> Given this, clinicians should consider the potential for high costs to patients and prescribe a lower-cost drug when clinically appropriate. Financial toxicity in cancer care has received widespread attention over the past decade,<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b41" ref-type="bibr">41</xref></sup> and our current work underscores that symptom control drugs can contribute to economic hardship for patients with cancer.</p><p>Our findings of the remarkably high costs of certain symptom control drugs should be interpreted in the context of widespread overuse of several of these drugs, especially when less expensive alternatives may be available.<sup><xref rid="b42" ref-type="bibr">42</xref></sup> Of the 10 ASCO Choosing Wisely recommendations published in 2012 and 2013, two focused on appropriate use of supportive care drugs (antiemetics and growth factors).<sup><xref rid="b43" ref-type="bibr">43</xref>,<xref rid="b44" ref-type="bibr">44</xref></sup> Notably, the evidence to support the use of certain symptom control drugs is limited, even for some widely used drugs, leading to a disconnect between true clinical benefit, putative clinical benefit, and out-of-pocket costs. As an example, megestrol acetate, which is commonly prescribed off-label for anorexia and cachexia,<sup><xref rid="b45" ref-type="bibr">45</xref></sup> lacks data supporting a meaningful improvement in quality of life and is associated with physical toxicity (eg, edema, thromboembolism, and adrenal insufficiency).<sup><xref rid="b33" ref-type="bibr">33</xref></sup> In the current work, we also now demonstrate the financial toxicity of megestrol acetate, as a prescription for brand-name megestrol acetate (Megace ES) can cost patients approximately $600 USD out of pocket for a 2-week fill. Costs to the health care system are also significant; Medicare part D spent close to $30 USD million on megestrol acetate in 2018.<sup><xref rid="b33" ref-type="bibr">33</xref></sup> In the case of multiple potential treatment options of similar or equal efficacy, out-of-pocket costs affect decision making.<sup><xref rid="b46" ref-type="bibr">46</xref></sup> Our findings highlight that when drug costs are high and expected clinical benefit is absent or low (eg, most drugs for anorexia and cachexia), the most appropriate action may be to not prescribe any drug. This do-nothing action can prevent financial toxicity, especially in patients with advanced cancer who may have limited time.<sup><xref rid="b46" ref-type="bibr">46</xref></sup></p><p>For several symptoms, nonpharmacologic interventions may be more effective than some of the drugs commonly used and should preferentially be used first. For example, with anorexia and cachexia, appropriate counseling and addressing patient and caregiver concerns about eating and weight loss are more likely to improve distress than drugs.<sup><xref rid="b34" ref-type="bibr">34</xref></sup> Additionally, for fatigue, addressing comorbid conditions and optimizing sleep and exercise are likely to be more effective than costly modafinil.<sup><xref rid="b47" ref-type="bibr">47</xref></sup> Payer noncoverage and high out-of-pocket costs of nonpharmacologic interventions (such as acupuncture or exercise regimens) for symptom control are partly responsible for their underutilization.<sup><xref rid="b48" ref-type="bibr">48</xref></sup> Our data demonstrate that even simple, seemingly innocuous drug prescriptions can cause significant economic consequences to patients. Patients are often given a handful of prescriptions; apart from cost considerations, reflexive prescription of symptom control drugs can contribute to polypharmacy, medication burden and nonadherence, and drug-drug interactions.</p><p>Our findings have several salient takeaways for clinicians to consider. First, we recognize that not all drugs for managing a particular symptom are bioequivalent. Costlier agents may very well be more appropriate, may improve patient quality of life, and prevent downstream health care use. Just like overuse, underuse of costly but appropriate antiemetics can also occur.<sup><xref rid="b49" ref-type="bibr">49</xref>,<xref rid="b50" ref-type="bibr">50</xref></sup> Thus, we call for appropriate use of symptom control drugs and not abandoning the use of costly agents altogether. Second, appropriate symptom control (often preventive) can help limit downstream spending on more costly drugs. As an example, most patients receiving opioids do not receive an appropriate prophylactic bowel regimen to prevent opioid-induced constipation; these patients can then develop refractory constipation, requiring the use of costly PAMORAs.<sup><xref rid="b51" ref-type="bibr">51</xref>-<xref rid="b53" ref-type="bibr">53</xref></sup> Third, payers commonly design prescription drug plans to cover generics over brand-name formulations.<sup><xref rid="b40" ref-type="bibr">40</xref></sup> Prescribing a generic over a brand-name drug can greatly influence costs. As an example, the lowest price of a 30-day prescription of generic versus brand-name duloxetine for chemotherapy-induced peripheral neuropathy would cost $12 USD versus $529 USD. Clinician-pharmacist partnerships and, in particular, leveraging the electronic medical record and the computerized provider order entry provide ideal opportunities to test and implement such interventions. Previous work has demonstrated that redesigning the electronic medical record default options can significantly increase generic prescriptions.<sup><xref rid="b54" ref-type="bibr">54</xref></sup> In addition to electronic health record&#8211;embedded Real-Time Benefit Tools available to clinicians,<sup><xref rid="b55" ref-type="bibr">55</xref></sup> pharmacist-led medication management strategies such as therapeutic (and generic) substitutions can reduce costs. When only brand-name drugs are available, as in the case of pancreatic enzymes, costs can be significant (&gt;$1,000 USD for just a 2-week supply). Clinicians and patients attempt to counter these high costs by rationing drugs, using nonregulated ineffective preparations, and using drug coupons.<sup><xref rid="b35" ref-type="bibr">35</xref>,<xref rid="b56" ref-type="bibr">56</xref></sup> Fourth, clinicians should be aware that costs of the same drug can vary substantially between different formulations: as an example, the lowest price for 15 units of 4 mg of generic metoclopramide is $3 USD for tablet and $60 USD for oral disintegrating tablet.</p><p>This study has several limitations. First, we describe costs for patients without (or those electing not to use) prescription drug coverage and we did not collect or analyze payer or coverage details for these drugs. Actual out-of-pocket costs for patients who have and choose to use prescription drug coverage will vary by the plan, product coverage, and benefit phase. However, since 45% of US adults age &lt; 65 years are inadequately covered, we believe that these data are widely applicable<sup><xref rid="b11" ref-type="bibr">11</xref></sup> Second, costs are dynamic and we provide only cross-sectional data from May 2021. Third, we present data for a single zip code (New York City) to be consistent with pricing information in ASCO guidelines. Drug costs are higher in large coastal cities, and although cost of living accounts for some of the geographical price variation, it is also related to the prevalence of the types of pharmacies in a region. In general, prices at big box and large chain pharmacies (such as Costco, Walgreens) are significantly lower than those at small or independent pharmacies.<sup><xref rid="b38" ref-type="bibr">38</xref></sup> The lowest cost for a patient in an area is likely to be at large pharmacy. The variation in lowest costs across zip codes is significantly less than the variation in the average of the average retail price (cash price) across a zip code, which is more affected by markups and the proportion of the types of pharmacies.<sup><xref rid="b38" ref-type="bibr">38</xref></sup></p><p>In conclusion, our findings highlight the high costs of many symptom control drugs and there is wide variation in the costs of drugs available to treat a particular cancer symptom. This work suggests that spending on symptom control can contribute substantially to patients' financial toxicity given the number of these products used and frequency of use among patients with cancer. These data may be helpful for patients and clinicians to re-evaluate the risk-benefit ratio of a prescription, especially in the context of the limited data to support the use of some of these symptom control drugs.</p></sec></body><back><fn-group content-type="presented-at"><title>PRIOR PRESENTATION</title><fn specific-use="presented-at" fn-type="presented-at"><p>Presented as abstract form at the 2021 ASCO Quality Care Symposium, September 24-25, 2021, held in Boston, MA.</p></fn></fn-group><fn-group content-type="supported-by"><title>SUPPORT</title><fn specific-use="supported-by" fn-type="supported-by"><p>A.G. and R.S. were supported by individual Conquer Cancer/the ASCO Foundation Young Investigator Awards. H.M.P. reports support from NIH P30 CA77598 Masonic Cancer Center and the Leukemia and Lymphoma society for unrelated work.</p></fn></fn-group><sec sec-type="COI-statement"><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><p>Disclosures provided by the authors are available with this article at DOI <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ascopubs.org/doi/full/10.1200/OP.21.00466" ext-link-type="uri">https://doi.org/10.1200/OP.21.00466</ext-link>.</p></sec><sec sec-type="contributed"><title>AUTHOR CONTRIBUTIONS</title><p><bold>Conception and design:</bold> Arjun Gupta, Ramy Sedhom, Helen M. Parsons, Anne H. Blaes, Ishwaria M. Subbiah, Ryan D. Nipp, Stacie B. Dusetzina</p><p><bold>Financial support:</bold> Arjun Gupta</p><p><bold>Administrative support:</bold> Arjun Gupta</p><p><bold>Provision of study materials or patients:</bold> Arjun Gupta</p><p><bold>Collection and assembly of data:</bold> Arjun Gupta, Udhayvir S. Grewal, Stacie B. Dusetzina</p><p><bold>Data analysis and interpretation:</bold> Arjun Gupta, Leonce Nshuti, Ramy Sedhom, Devon K. Check, Helen M. Parsons, Anne H. Blaes, Beth A. Virnig, Maryam B. Lustberg, Ishwaria M. Subbiah, Ryan D. Nipp, Sydney M. Dy, Stacie B. Dusetzina</p><p><bold>Manuscript writing:</bold> All authors</p><p><bold>Final approval of manuscript:</bold> All authors</p><p><bold>Accountable for all aspects of the work:</bold> All authors</p></sec><sec sec-type="COI-statement"><title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title><sec><title>Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms</title><p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://ascopubs.org/op/authors/author-center" ext-link-type="uri">ascopubs.org/op/authors/author-center</ext-link>.</p><p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p></sec><sec><title>Devon K. Check</title><p><bold>Research Funding:</bold> AstraZeneca</p></sec><sec><title>Maryam B. Lustberg</title><p><bold>Honoraria:</bold> Novartis, bioTheranostics</p><p><bold>Consulting or Advisory Role:</bold> PledPharma, Disarm Therapeutics, Pfizer</p><p><bold>Other Relationship:</bold> Cynosure/Hologic</p></sec><sec><title>Ishwaria M. Subbiah</title><p><bold>Consulting or Advisory Role:</bold> MedImmune (I)</p><p><bold>Research Funding:</bold> Bayer (I), Novartis (I), GlaxoSmithKline (I), NanoCarrier (I), Celgene (I), Northwest Biotherapeutics (I), Incyte (I), Fujifilm (I), Pfizer (I), Amgen (I), AbbVie (I), Multivir (I), Exelixis (I), Loxo (I), Blueprint Medicines (I), Takeda (I)</p><p><bold>Travel, Accommodations, Expenses:</bold> Bayer (I), PharmaMar (I), Novartis (I), MedImmune (I)</p></sec><sec><title>Stacie B. Dusetzina</title><p><bold>Other Relationship:</bold> Institute for Clinical and Economic Review, Arnold Ventures, Leukemia and Lymphoma Society, The Commonwealth Fund, West Health, National Academy of State Health Policy, Robert Wood Johnson Foundation, Medicare Payment Advisory Commission</p><p>No other potential conflicts of interest were reported.</p></sec></sec><app-group><app id="app1"><title>APPENDIX</title><p>
<fig position="anchor" id="figA1" fig-type="figure" orientation="portrait"><label>FIG A1.</label><caption><p>Range of costs of drugs used to manage chemotherapy-induced peripheral neuropathy for a typical fill (1 month). USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g005.jpg"/></fig>
<fig position="anchor" id="figA2" fig-type="figure" orientation="portrait"><label>FIG A2.</label><caption><p>Range of costs of drugs used to manage constipation for a typical fill (2 weeks). USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g006.jpg"/></fig>
<fig position="anchor" id="figA3" fig-type="figure" orientation="portrait"><label>FIG A3.</label><caption><p>Range of costs of drugs used to manage diarrhea for a typical fill (7 days). USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g007.jpg"/></fig>
<fig position="anchor" id="figA4" fig-type="figure" orientation="portrait"><label>FIG A4.</label><caption><p>Range of costs of drugs used to manage exocrine pancreatic insufficiency for a typical fill (2 weeks). USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g008.jpg"/></fig>
<fig position="anchor" id="figA5" fig-type="figure" orientation="portrait"><label>FIG A5.</label><caption><p>Range of costs of drugs used to treat chemotherapy-induced nausea and vomiting for a typical fill (7 days). 5-HT3, serotonin; USD, US dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="op-18-0140-g009.jpg"/></fig>
</p></app></app-group><ref-list><title>REFERENCES</title><ref id="b1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dusetzina</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Huskamp</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Keating</surname><given-names>NL</given-names></name></person-group>: <article-title>Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019</article-title>. <source>JAMA</source><volume>321</volume>:<fpage>2025</fpage>-<lpage>2027</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31135837</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.4492</pub-id><pub-id pub-id-type="pmcid">PMC6547115</pub-id></mixed-citation></ref><ref id="b2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedhom</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chino</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name></person-group>: <article-title>Financial toxicity and cancer care #409</article-title>. <source>J Palliat Med</source><volume>24</volume>:<fpage>453</fpage>-<lpage>454</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33650911</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jpm.2020.0699</pub-id></mixed-citation></ref><ref id="b3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Premnath</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sumarsono</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sedhom</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Use of peripheral mu-opioid receptor antagonists for treating opioid-induced constipation among US Medicare beneficiaries from 2014 to 2018</article-title>. <source>J Palliat Med</source><volume>24</volume>:<fpage>1236</fpage>-<lpage>1239</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33872062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jpm.2021.0021</pub-id></mixed-citation></ref><ref id="b4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>SA</given-names></name>, <etal>et al</etal></person-group>: <article-title>Use of bone-modifying agents among Medicare beneficiaries with multiple myeloma</article-title>. <source>JAMA Oncol</source><volume>6</volume>:<fpage>296</fpage>-<lpage>298</lpage>, <year>2020</year><pub-id pub-id-type="pmid">31830210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2019.5426</pub-id><pub-id pub-id-type="pmcid">PMC6990751</pub-id></mixed-citation></ref><ref id="b5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doshi</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Huo</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>: <article-title>Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents</article-title>. <source>J Clin Oncol</source><volume>36</volume>:<fpage>476</fpage>-<lpage>482</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29261440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.74.5091</pub-id></mixed-citation></ref><ref id="b6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Premnath</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Grewal</surname><given-names>US</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name></person-group>: <article-title>Park the parking</article-title>. <source>JCO Oncol Pract</source><volume>16</volume>:<fpage>215</fpage>-<lpage>217</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32243240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/OP.20.00065</pub-id><pub-id pub-id-type="pmcid">PMC7444643</pub-id></mixed-citation></ref><ref id="b7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gewandter</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Kleckner</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>JH</given-names></name>, <etal>et al</etal></person-group>: <article-title>Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: An NIH collaboratory study of claims data</article-title>. <source>Support Care Cancer</source><volume>28</volume>:<fpage>2553</fpage>-<lpage>2562</lpage>, <year>2020</year><pub-id pub-id-type="pmid">31494735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-019-05063-x</pub-id><pub-id pub-id-type="pmcid">PMC7060096</pub-id></mixed-citation></ref><ref id="b8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hershman</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Lacchetti</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Dworkin</surname><given-names>RH</given-names></name>, <etal>et al</etal></person-group>: <article-title>Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline</article-title>. <source>J Clin Oncol</source><volume>32</volume>:<fpage>1941</fpage>-<lpage>1967</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24733808</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2013.54.0914</pub-id></mixed-citation></ref><ref id="b9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hesketh</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Kris</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Basch</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>Antiemetics: American Society of Clinical Oncology clinical practice guideline update</article-title>. <source>J Clin Oncol</source><volume>35</volume>:<fpage>3240</fpage>-<lpage>3261</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28759346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.74.4789</pub-id></mixed-citation></ref><ref id="b10"><label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Center for Health Statistics</collab></person-group>: <source>Health Insurance Coverage</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/fastats/health-insurance.htm" ext-link-type="uri">https://www.cdc.gov/nchs/fastats/health-insurance.htm</ext-link></mixed-citation></ref><ref id="b11"><label>11.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Bhupal</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Doty</surname><given-names>MM</given-names></name></person-group>: <source>The Commonwealth Fund. Health Insurance Coverage Eight Years After the ACA</source>, <year>2019</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.commonwealthfund.org/publications/issue-briefs/2019/feb/health-insurance-coverage-eight-years-after-aca" ext-link-type="uri">https://www.commonwealthfund.org/publications/issue-briefs/2019/feb/health-insurance-coverage-eight-years-after-aca</ext-link></mixed-citation></ref><ref id="b12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>TB</given-names></name>, <name name-style="western"><surname>Adler</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Forsmark</surname><given-names>CE</given-names></name>, <etal>et al</etal></person-group>: <article-title>ACG clinical guideline: Chronic pancreatitis</article-title>. <source>Am J Gastroenterol</source><volume>115</volume>:<fpage>322</fpage>-<lpage>339</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32022720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000000535</pub-id></mixed-citation></ref><ref id="b13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hesketh</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Kris</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Basch</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>Antiemetics: ASCO guideline update</article-title>. <source>J Clin Oncol</source><volume>38</volume>:<fpage>2782</fpage>-<lpage>2797</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32658626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.01296</pub-id></mixed-citation></ref><ref id="b14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkin</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Cherny</surname><given-names>NI</given-names></name>, <name name-style="western"><surname>La Carpia</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>: <article-title>Diagnosis, assessment and management of constipation in advanced cancer: ESMO clinical practice guidelines</article-title>. <source>Ann Oncol</source><volume>29</volume>:<fpage>iv111</fpage>-<lpage>iv125</lpage>, <year>2018</year><pub-id pub-id-type="pmid">30016389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdy148</pub-id></mixed-citation></ref><ref id="b15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McKenzie</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Zaki</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Raman</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>Radiation-induced nausea and vomiting: A comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines</article-title>. <source>Support Care Cancer</source><volume>27</volume>:<fpage>783</fpage>-<lpage>791</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30607675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-018-4586-2</pub-id></mixed-citation></ref><ref id="b16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roeland</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Bohlke</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Baracos</surname><given-names>VE</given-names></name>, <etal>et al</etal></person-group>: <article-title>Management of cancer cachexia: ASCO guideline</article-title>. <source>J Clin Oncol</source><volume>38</volume>:<fpage>2438</fpage>-<lpage>2453</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32432946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.00611</pub-id></mixed-citation></ref><ref id="b17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bower</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bak</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Berger</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Screening, assessment, and management of fatigue in adult survivors of cancer: An American Society of Clinical Oncology clinical practice guideline adaptation</article-title>. <source>J Clin Oncol</source><volume>32</volume>:<fpage>1840</fpage>-<lpage>1850</lpage>, <year>2014</year><pub-id pub-id-type="pmid">24733803</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2013.53.4495</pub-id><pub-id pub-id-type="pmcid">PMC4039870</pub-id></mixed-citation></ref><ref id="b18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></name>, <name name-style="western"><surname>Ajani</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Catalano</surname><given-names>RB</given-names></name>, <etal>et al</etal></person-group>: <article-title>Recommended guidelines for the treatment of cancer treatment-induced diarrhea</article-title>. <source>J Clin Oncol</source><volume>22</volume>:<fpage>2918</fpage>-<lpage>2926</lpage>, <year>2004</year><pub-id pub-id-type="pmid">15254061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2004.04.132</pub-id></mixed-citation></ref><ref id="b19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bossi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Antonuzzo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cherny</surname><given-names>NI</given-names></name>, <etal>et al</etal></person-group>: <article-title>Diarrhoea in adult cancer patients: ESMO clinical practice guidelines</article-title>. <source>Ann Oncol</source><volume>29</volume>:<fpage>iv126</fpage>-<lpage>iv142</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29931177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdy145</pub-id></mixed-citation></ref><ref id="b20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crockett</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Greer</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Heidelbaugh</surname><given-names>JJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>American gastroenterological association Institute guideline on the medical management of opioid-induced constipation</article-title>. <source>Gastroenterology</source><volume>156</volume>:<fpage>218</fpage>-<lpage>226</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30340754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.07.016</pub-id></mixed-citation></ref><ref id="b21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>TJ</given-names></name></person-group>: <article-title>Geriatrics and palliative care: All in the same family</article-title>. <source>Clin Geriatr Med</source><volume>31</volume>:<fpage>xi</fpage>-<lpage>xii</lpage>, <year>2015</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cger.2015.02.001</pub-id><pub-id pub-id-type="pmid">25920065</pub-id></mixed-citation></ref><ref id="b22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bhargava</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fatigoni</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>: <article-title>Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment</article-title>. <source>Ann Oncol</source><volume>31</volume>:<fpage>713</fpage>-<lpage>723</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32173483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.02.016</pub-id></mixed-citation></ref><ref id="b23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Margulies</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cardoso</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>: <article-title>Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up</article-title>. <source>Ann Oncol</source><volume>31</volume>:<fpage>1306</fpage>-<lpage>1319</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32739407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.07.003</pub-id></mixed-citation></ref><ref id="b24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roila</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Molassiotis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Herrstedt</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients</article-title>. <source>Ann Oncol</source><volume>27</volume>:<fpage>v119</fpage>-<lpage>v33</lpage>, <year>2016</year><pub-id pub-id-type="pmid">27664248</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdw270</pub-id></mixed-citation></ref><ref id="b25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bubis</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Davis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Mahar</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Symptom burden in the first year after cancer diagnosis: An analysis of patient-reported outcomes</article-title>. <source>J Clin Oncol</source><volume>36</volume>:<fpage>1103</fpage>-<lpage>1111</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29494259</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2017.76.0876</pub-id></mixed-citation></ref><ref id="b26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleeland</surname><given-names>CS</given-names></name></person-group>: <article-title>Symptom burden: Multiple symptoms and their impact as patient-reported outcomes</article-title>. <source>J Natl Cancer Inst Monogr</source>:<fpage>16</fpage>-<lpage>21</lpage>, <year>2007</year><pub-id pub-id-type="pmid">17951226</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jncimonographs/lgm005</pub-id></mixed-citation></ref><ref id="b27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name></person-group>: <article-title>Management of cancer therapy-associated oral mucositis</article-title>. <source>JCO Oncol Pract</source><volume>16</volume>:<fpage>103</fpage>-<lpage>109</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32048926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JOP.19.00652</pub-id></mixed-citation></ref><ref id="b28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Henry</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Loprinzi</surname><given-names>CL</given-names></name></person-group>: <article-title>Management of aromatase inhibitor-induced musculoskeletal symptoms</article-title>. <source>JCO Oncol Pract</source><volume>16</volume>:<fpage>733</fpage>-<lpage>739</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32780640</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/OP.20.00113</pub-id></mixed-citation></ref><ref id="b29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sedhom</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Nonpharmacological interventions for managing breathlessness in patients with advanced cancer: A systematic review</article-title>. <source>JAMA Oncol</source><volume>7</volume>:<fpage>290</fpage>-<lpage>298</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33211072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2020.5184</pub-id></mixed-citation></ref><ref id="b30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bohlke</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>: <article-title>Management of dyspnea in advanced cancer: ASCO guideline</article-title>. <source>J Clin Oncol</source><volume>39</volume>:<fpage>1389</fpage>-<lpage>1411</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33617290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.20.03465</pub-id></mixed-citation></ref><ref id="b31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>KKF</given-names></name>, <name name-style="western"><surname>Lalla</surname><given-names>RV</given-names></name>, <etal>et al</etal></person-group>: <article-title>MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy</article-title>. <source>Cancer</source><volume>126</volume>:<fpage>4423</fpage>-<lpage>4431</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32786044</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cncr.33100</pub-id><pub-id pub-id-type="pmcid">PMC7540329</pub-id></mixed-citation></ref><ref id="b32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feliciano</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Waldfogel</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Pharmacologic interventions for breathlessness in patients with advanced cancer: A systematic review and meta-analysis</article-title>. <source>JAMA Netw Open</source><volume>4</volume>:<fpage>e2037632</fpage>, <year>2021</year><pub-id pub-id-type="pmid">33630086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.37632</pub-id><pub-id pub-id-type="pmcid">PMC7907959</pub-id></mixed-citation></ref><ref id="b33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Gandhi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>TJ</given-names></name>, <etal>et al</etal></person-group>: <article-title>Lessons from spending on megestrol for cancer cachexia</article-title>. <source>Support Care Cancer</source><volume>29</volume>:<fpage>5553</fpage>-<lpage>5555</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33893560</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-021-06240-7</pub-id></mixed-citation></ref><ref id="b34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kabani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dy</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name></person-group>: <article-title>The key role of nonpharmacologic management of cachexia in persons with advanced illness: A teachable moment</article-title>. <source>JAMA Intern Med</source><volume>181</volume>:<fpage>978</fpage>-<lpage>979</lpage>, <year>2021</year><pub-id pub-id-type="pmid">33900359</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2021.1533</pub-id></mixed-citation></ref><ref id="b35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Premnath</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sedhom</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>: <article-title>Projected 30-day out-of-pocket costs and total spending on pancreatic enzyme replacement therapy under Medicare Part D</article-title>. <source>Pancreatology</source><volume>21</volume>:<fpage>1009</fpage>-<lpage>1010</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34006458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pan.2021.05.002</pub-id></mixed-citation></ref><ref id="b36"><label>36.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>GoodRx, Inc</collab></person-group>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://GoodRx.com" ext-link-type="uri">GoodRx.com</ext-link></mixed-citation></ref><ref id="b37"><label>37.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>GoodRx Holdings Inc</collab></person-group>: <source>S-1 Registration Statement</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>US Securities and Exchange Commission</publisher-name>, <year>2020</year></mixed-citation></ref><ref id="b38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kulldorff</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sarpatwari</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Variation in prescription drug prices by retail pharmacy type: A national cross-sectional study</article-title>. <source>Ann Intern Med</source><volume>171</volume>:<fpage>605</fpage>-<lpage>611</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31569218</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/M18-1138</pub-id></mixed-citation></ref><ref id="b39"><label>39.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Center for Health Policy &amp; Outcomes. Memorial Sloan Kettering Cancer Center</collab></person-group>: <source>Price &amp; Value of Cancer Drug. Methods for Drug Price Calculations</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mskcc.org/sites/default/files/node/25097/documents/methods-for-drug-price-calculations-081517.pdf" ext-link-type="uri">https://www.mskcc.org/sites/default/files/node/25097/documents/methods-for-drug-price-calculations-081517.pdf</ext-link></mixed-citation></ref><ref id="b40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dusetzina</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Cubanski</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nshuti</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>Medicare Part D plans rarely cover brand-name drugs when generics are available</article-title>. <source>Health Aff (Millwood)</source><volume>39</volume>:<fpage>1326</fpage>-<lpage>1333</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32744944</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2019.01694</pub-id><pub-id pub-id-type="pmcid">PMC9297534</pub-id></mixed-citation></ref><ref id="b41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zafar</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Abernethy</surname><given-names>AP</given-names></name></person-group>: <article-title>Financial toxicity, Part I: A new name for a growing problem</article-title>. <source>Oncology (Williston Park)</source><volume>27</volume>:<fpage>80</fpage>-<lpage>81, 149</lpage>, <year>2013</year><pub-id pub-id-type="pmid">23530397</pub-id><pub-id pub-id-type="pmcid">PMC4523887</pub-id></mixed-citation></ref><ref id="b42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schleicher</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Bach</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Matsoukas</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>: <article-title>Medication overuse in oncology: Current trends and future implications for patients and society</article-title>. <source>Lancet Oncol</source><volume>19</volume>:<fpage>e200</fpage>-<lpage>e208</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29611528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(18)30099-8</pub-id><pub-id pub-id-type="pmcid">PMC6207078</pub-id></mixed-citation></ref><ref id="b43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnipper</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Lyman</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Blayney</surname><given-names>DW</given-names></name>, <etal>et al</etal></person-group>: <article-title>American Society of Clinical Oncology 2013 top five list in oncology</article-title>. <source>J Clin Oncol</source><volume>31</volume>:<fpage>4362</fpage>-<lpage>4370</lpage>, <year>2013</year><pub-id pub-id-type="pmid">24170249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2013.53.3943</pub-id></mixed-citation></ref><ref id="b44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnipper</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Raghavan</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>: <article-title>American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: The top five list for oncology</article-title>. <source>J Clin Oncol</source><volume>30</volume>:<fpage>1715</fpage>-<lpage>1724</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22493340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2012.42.8375</pub-id></mixed-citation></ref><ref id="b45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Shamliyan</surname><given-names>TA</given-names></name></person-group>: <article-title>Off-label megestrol in patients with anorexia-cachexia syndrome associated with malignancy and its treatments</article-title>. <source>Am J Med</source><volume>131</volume>:<fpage>623</fpage>-<lpage>629.e1</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29784194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2017.12.028</pub-id></mixed-citation></ref><ref id="b46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henrikson</surname><given-names>NB</given-names></name>, <name name-style="western"><surname>Shankaran</surname><given-names>V</given-names></name></person-group>: <article-title>Improving price transparency in cancer care</article-title>. <source>JCO Oncol Pract</source><volume>12</volume>:<fpage>44</fpage>-<lpage>47</lpage>, <year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JOP.2015.006171</pub-id><pub-id pub-id-type="pmid">26759467</pub-id></mixed-citation></ref><ref id="b47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popescu</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Roila</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Arends</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>: <article-title>Supportive care: Low cost, high value</article-title>. <source>Am Soc Clin Oncol Ed Book</source><volume>41</volume>:<fpage>1</fpage>-<lpage>11</lpage>, <year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_320041</pub-id><pub-id pub-id-type="pmid">33830830</pub-id></mixed-citation></ref><ref id="b48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedhom</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>: <article-title>Payer coverage of integrative medicine interventions for symptom control in patients with cancer</article-title>. <source>JCO Oncol Pract</source><volume>17</volume>:<fpage>587</fpage>-<lpage>590</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34310190</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/OP.21.00361</pub-id></mixed-citation></ref><ref id="b49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahendraratnam</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Farley</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Basch</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>: <article-title>Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy</article-title>. <source>Support Care Cancer</source><volume>27</volume>:<fpage>4525</fpage>-<lpage>4534</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30915567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-019-04730-3</pub-id></mixed-citation></ref><ref id="b50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roeland</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Ruddy</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>LeBlanc</surname><given-names>TW</given-names></name>, <etal>et al</etal></person-group>: <article-title>What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy</article-title>. <source>J Natl Compr Canc Netw</source><volume>18</volume>:<fpage>676</fpage>-<lpage>681</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32502985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.6004/jnccn.2019.7526</pub-id></mixed-citation></ref><ref id="b51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Keshvani</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>: <article-title>Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: A retrospective cohort study</article-title>. <source>Support Care Cancer</source><volume>28</volume>:<fpage>5315</fpage>-<lpage>5321</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32124025</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-020-05364-6</pub-id></mixed-citation></ref><ref id="b52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nathani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name></person-group>: <article-title>Preventing opioid-induced constipation: A teachable moment</article-title>. <source>JAMA Intern Med</source><volume>180</volume>:<fpage>1371</fpage>-<lpage>1372</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32832983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2020.3285</pub-id></mixed-citation></ref><ref id="b53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Nathani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gupta</surname><given-names>A</given-names></name></person-group>: <article-title>Preventing opioid-induced constipation-reply</article-title>. <source>JAMA Intern Med</source><volume>181</volume>:<fpage>726</fpage>-<lpage>727</lpage>, <year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2020.8886</pub-id><pub-id pub-id-type="pmid">33616614</pub-id></mixed-citation></ref><ref id="b54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Halpern</surname><given-names>SD</given-names></name>, <etal>et al</etal></person-group>: <article-title>Generic medication prescription rates after health system-wide redesign of default options within the electronic health record</article-title>. <source>JAMA Intern Med</source><volume>176</volume>:<fpage>847</fpage>-<lpage>848</lpage>, <year>2016</year><pub-id pub-id-type="pmid">27159011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamainternmed.2016.1691</pub-id><pub-id pub-id-type="pmcid">PMC7240800</pub-id></mixed-citation></ref><ref id="b55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Frisse</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Dusetzina</surname><given-names>SB</given-names></name></person-group>: <article-title>Real-time benefit Tools for drug prices</article-title>. <source>JAMA</source><volume>322</volume>:<fpage>2383</fpage>-<lpage>2384</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31651954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2019.16434</pub-id></mixed-citation></ref><ref id="b56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forsmark</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group>: <article-title>The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent</article-title>. <source>Aliment Pharmacol Ther</source><volume>51</volume>:<fpage>958</fpage>-<lpage>967</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32249970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.15698</pub-id><pub-id pub-id-type="pmcid">PMC7299155</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>